Company Vision and Mission - Claritev aims to make healthcare transparent and affordable for all[14, 25] - The company has identified potential savings of $247 billion for 60 million health plan members[18] - Claritev processed $1776 billion in claim charges[18] Market Challenges and Opportunities - The healthcare industry faces escalating costs, with medical inflation at 85% and employer costs increasing by 8-10%[23] - There is $1 trillion in healthcare waste[23] - Claritev's expansion initiatives can potentially double its addressable market, with a long-term international opportunity exceeding $1 billion[36, 35] Financial Performance - PSAV claim volume decreased by approximately 13% year-over-year from Q3'24 to Q3'25[51] - However, potential savings identified per claim increased by 10% year-over-year, and revenue per claim increased by 19% year-over-year[51] - PSAV revenue increased by $6 million sequentially from Q2'25 to Q3'25[51] Debt Structure - As of September 30, 2025, Claritev's total long-term debt was $4670 billion, with net debt at $4631 billion[61] - The total leverage ratio, net of cash, was 78x[61]

Market Opportunity & Performance - The company operates in a large and underpenetrated market, with 75 million people facing mental health conditions[5] - 40%+ of Talkspace patients are new to therapy[5] - The U S Behavioral Health Market is projected to have a CAGR of 7 9% from 2025E to 2030E[5] - The company has demonstrated top-line growth with a 24% revenue CAGR from 2022 to 2025E[6] - The company is experiencing profitability with 115% YoY EBITDA Growth[9] Growth Strategy - The company is focused on expanding coverage and activating lives through diversified growth strategies[13] - The company is driving consumer awareness through diversified channels, including paid media, organic initiatives, and partnerships[14] - The company is establishing strategic partnerships to drive high-intent referrals[18] - The company is improving the patient journey, leading to a +22% checkout conversion rate and +50% members completing 3 sessions in month 1[23] - The company is expanding its offerings to include psychiatry, social health, military & Medicare, and youth services[25, 26, 27] AI Initiatives - The company is developing a "safe" AI agent specifically designed for mental health support, utilizing clinically recognized standards of care with continuous human oversight, and privacy (HIPAA) protection[31] - The company's AI agent is trained on a massive mental health dataset to improve risk recognition, support appropriate decision-making, and avoid the pitfalls already seen in general-purpose AI systems[32]

First Horizon (NYSE:FHN) Q4 2025 Earnings call January 15, 2026 09:30 AM ET Speaker4Hello, everyone, and thank you for joining the First Horizon Fourth Quarter 2025 earnings conference call. My name is Lucy, and I'll be coordinating your call today. During the presentation, you can register a question by pressing star followed by one on your telephone keypad. If you change your mind, please press star followed by two. It is now my pleasure to hand over to your host, Tyler Craft, Head of Investor Relations, ...

HCV Program (BEM/RZR) - The company is developing BEM/RZR as a potential best-in-class treatment for HCV, with Phase 3 trials underway[7, 12] - Phase 2 results showed a 98% sustained virologic response (SVR12) with the BEM/RZR combination regimen[12] - Two Phase 3 trials, C-BEYOND (US/Canada) and C-FORWARD (outside North America), are enrolling approximately 1,760 patients in total[12, 30] - The US sees over 160 thousand new chronic HCV infections annually, while approximately 90 thousand are treated, highlighting the need for improved treatment strategies[18] - Market research indicates that 48% of non-cirrhotic patients and 49% of compensated cirrhotic patients are likely to be prescribed BEM/RZR[21] HEV Program (AT-587) - A new program is focused on Hepatitis E Virus (HEV) with product candidate AT-587, targeting Phase 1 initiation in mid-2026[7] - The WHO estimates up to 20 million global HEV infections annually[42] - Approximately 3% of at-risk patients develop chronic HEV, leading to a potential treatment population of ~135 thousand patients annually[51] - The commercial opportunity for HEV treatment in the US & EU is estimated at $750 million to $1 billion[50, 51] - AT-587 demonstrates potent antiviral activity against multiple HEV-3 strains and ribavirin-resistant virus[53] Financial Status - The company reported cash and investments of $3018 million as of December 31, 2025, with a cash runway anticipated through 2027[7, 61]

PAPZIMEOS Approval and Launch - PAPZIMEOS received full FDA approval in 2025 for treating all adults with RRP, regardless of disease severity[10, 14] - PAPZIMEOS is the first and only FDA-approved therapy for adults with RRP, targeting the underlying cause of the disease[16] - The company commenced the commercial US launch of PAPZIMEOS and initiated its commercial manufacturing campaign in 2025[10] - Over 50 accounts, including academic and community settings, have prescribed PAPZIMEOS[33] - The company has seen a rapid increase in unaided brand awareness of PAPZIMEOS across academic and community settings[34] Clinical Data and Efficacy - Clinical data shows a 51% complete response rate with PAPZIMEOS, with durable ongoing complete responses[21] - PAPZIMEOS significantly reduced the number of surgeries required post-treatment, with p<0001[22] - Median duration of follow-up was at 36 months (27-37), and the median duration of complete response has yet to be reached[25] Market Opportunity and Expansion - The prevalence of RRP in the US is approximately 27000 adult patients, suggesting a multi-billion-dollar revenue potential[30] - The prevalence of RRP ex-US is approximately 35000 adults in EU4, UK, and Japan, approximately 50000 adults in the rest of EU and select markets, and approximately 85000 adults in China, suggesting a multi-billion-dollar revenue potential[30] - The company anticipates PAPZIMEOS regulatory expansion to the EU and Japan[37] Financials and Future Milestones - The company secured up to $125 million in non-dilutive funding to fortify its balance sheet[10] - The company aims to achieve positive cash flow in 2026 by continuing execution and expansion to maximize the PAPZIMEOS market opportunity[37]

January 15, 2026 Fourth Quarter 2025 H.B. Fuller Earnings Conference Call 1200 Willow Lake Blvd, St Paul, Minnesota 55110 www.hbfuller.com January 15, 2026 Disclosure Certain matters discussed today are forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements reflect our current expectations, and actual results may differ as they are subjec ...

The Goldman Sachs Group (NYSE:GS) Q4 2025 Earnings call January 15, 2026 09:30 AM ET Speaker0Good morning. My name is Katie Annale, your conference facilitator today. I would like to welcome everyone to the Goldman Sachs Fourth Quarter 2025 earnings conference call. On behalf of Goldman Sachs, I will begin the call with the following disclaimer. The earnings presentation can be found on the investor relations page of the Goldman Sachs website and contains information on forward-looking statements and non-GA ...

NeurAxis (NYSEAM:NRXS) FY Conference January 15, 2026 09:30 AM ET Company ParticipantsBrian Carrico - CEOBen Shamsian - VP of Investor RelationsBen ShamsianHello, and welcome to NeurAxis Company Webcast. My name is Ben Shamsian, Vice President of Lytham Partners, and today, Brian Carrico, CEO of NeurAxis, will be taking us through a brief slide presentation, followed by a fireside chat moderated by me. As a reminder, NeurAxis trades under the ticker NRXS. With that, let's get started. Brian, welcome.Brian C ...

Summary of GRI Bio Inc. Extraordinary General Meeting Company Overview - **Company Name**: GRI Bio Inc. - **Stock Symbol**: NasdaqCM: GRI - **Meeting Date**: January 15, 2026 Key Points Discussed Meeting Attendance and Quorum - A total of **4,874,725 shares** were present, representing **48.16%** of the outstanding voting stock, confirming a quorum for the meeting [2] Proposals Voted Upon 1. **Amendment Proposal**: - Approval of an amendment to the Amended and Restated Certificate of Incorporation to effect a **reverse stock split** of the company's Common Stock at a ratio between **1 for 2** and **1 for 30**. - The exact ratio will be determined by the Board of Directors, and they have the discretion to abandon the proposed amendment [3] 2. **Adjournment Proposal**: - Approval for the adjournment of the special meeting to a later date if necessary, to allow further solicitation and voting of proxies in case there are insufficient votes for the amendment proposal [4] Voting Process - Voting was conducted via proxy and electronic ballot, with an option for stockholders to vote during the meeting [5] - Preliminary results indicated that both the amendment and adjournment proposals received the requisite votes for approval [5] Conclusion of Meeting - Both proposals were declared duly approved, with final voting results expected to be reported on Form 8-K to the SEC within four business days [6] - The meeting concluded with appreciation expressed to stockholders for their participation [6][7] Additional Important Information - The meeting was attended by key executives including the CEO, CFO, and legal counsel, indicating a structured approach to governance and compliance [1] - The ability for the Board to abandon the reverse stock split proposal highlights a level of flexibility in corporate governance [3]

Financial Performance Highlights - The company's total assets reached $1963640 thousand, a 38% increase compared to 2021's $1350549 thousand [76] - Net income for the year was $43069 thousand, a decrease of 58% compared to 2024's $45698 thousand [76] - Diluted earnings per share were $450, down 70% from $484 in the previous year [76] - Return on average assets was 237%, a decrease of 108% compared to 265% in the previous year [77] - The efficiency ratio was 4024%, compared to 3790% the previous year [77] Loan and Deposit Portfolio - Total loans amounted to $1606431 thousand, up 15% from $1397383 thousand in the previous year [76] - Total deposits reached $1700833 thousand, up 122% from $1515471 thousand in the previous year [76] - Non-interest-bearing deposits constitute 201% of total deposits, amounting to $3414 million [56] Capital and Shareholder Returns - Tangible book value per share increased to $2526, reflecting a CAGR of 168% since 2018 [23] - The company's dividend payout ratio is 217%, lower than the average 35% for dividend-paying banks [3] - Total shareholder return since the IPO is 1614%, outperforming the median of public banks by 1262% [37]